A Phase ???, Randomized, Double-Blinded Study Evaluating the Safety and Efficacy of Combination Treatment of Motixafortide and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma
Latest Information Update: 01 Dec 2024
At a glance
- Drugs Motixafortide (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Guangzhou Gloria Biosciences
- 25 Nov 2024 According to a BioLineRx media release, IND was filed and approved by the Center for Drug Evaluation of the National Medical Products Administration in China. Anticipate initiation of pivotal clinical trial in 1H 2025.
- 26 Jul 2024 New trial record